Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cost-Effectiveness Study of Pegylated Recombinant Human Granulocyte Colony-stimulating Factor(PEG-rhG-CSF) in Prophylactic Treatment of Neutropenia After Chemotherapy in Lymphoma

NCT04083079 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT04083079
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04083079 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cost-Effectiveness Study of Pegylated Recombinant Human Granulocyte Colony-stimulating Factor(PEG-rhG-CSF) in Prophylactic Treatment of Neutropenia After Chemotherapy in Lymphoma
Lead sponsor
Ruijin Hospital
Phase
Phase 4
Overall status
Unknown status
Start date
August 1, 2019
Completion date
April 1, 2022
Enrollment
250 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cost-benefit analysis, granulocyte colony-stimulating factor, lymphoma, non-hodgkin